The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Abstract
Among the products of enteroendocrine cells are the incretins glucagon-like peptide-1 (GLP-1, secreted by L cells) and glucose-dependent insulinotropic peptide (GIP, secreted by K cells). These are key modulators of insulin secretion, glucose homeostasis, and gastric emptying. Because of the rapid early rise of GLP-1 in plasma after oral glucose, we wished to definitively establish the absence or presence of L cells, as well as the relative distribution of the incretin cell types in human duodenum. We confirmed the presence of proglucagon and pro-GIP genes, their products, and glucosensory molecules by tissue immunohistochemistry and RT-PCR of laser-captured, single duodenal cells. We also assayed plasma glucose, incretin, and insulin levels in subjects with normal glucose tolerance and type 2 diabetes for 120 min after they ingested 75 g of glucose. Subjects with normal glucose tolerance ( n = 14) had as many L cells (15 ± 1), expressed per 1,000 gut epithelial cells, as K cells (13 ± 1), with some containing both hormones (L/K cells, 5 ± 1). In type 2 diabetes, the number of L and L/K cells was increased (26 ± 2; P < 0.001 and 9 ± 1; P < 0.001, respectively). Both L and K cells contained glucokinase and glucose transporter-1, -2, and -3. Newly diagnosed type 2 diabetic subjects had increased plasma GLP-1 levels between 20 and 80 min, concurrently with rising plasma insulin levels. Significant coexpression of the main incretin peptides occurs in human duodenum. L and K cells are present in equal numbers. New onset type 2 diabetes is associated with a shift to the L phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“Contrary to reports from subjects with long-standing T2DM (47, 59), in newly diagnosed subjects late-phase GLP-1 release was augmented, concomitant with rising plasma insulin levels.”
ResultZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“Pharmacological concentrations of exogenous GLP-1 (45, 60, 62), GLP-1 analogs resistant to DPP IV (24, 48), and GLP-1 receptor agonists (16) can normalize blood glucose levels and improve early-phase insulin secretion in T2DM, restoring “glucose competence” to -cells in the process.”
BackgroundNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Pharmacological concentrations of exogenous GLP-1 (45, 60, 62), GLP-1 analogs resistant to DPP IV (24, 48), and GLP-1 receptor agonists (16) can normalize blood glucose levels and improve early-phase insulin secretion in T2DM, restoring “glucose competence” to -cells in the process.”
BackgroundTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 601
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Lundberg, J. M., Tatemoto, K., Terenius, L., Hellström, P. M., Mutt, V, Hökfelt, T., & Hamberger, B. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.14.4471 · Cited by 405
Deacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Gribble, F. M., Williams, L., Simpson, A. K., & Reimann, F. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1147 · Cited by 393
GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine
Mortensen, K., Christensen, L. L., Holst, J. J., & Orskov, C. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00125-3 · Cited by 359
Regulation of Pancreatic β-Cell Glucokinase
Matschinsky, F. M. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s394 · Cited by 345
Brittan, M., & Wright, N. A. (2002) · The Journal of Pathology · doi:10.1002/path.1155 · Cited by 334
The New Biology of Gastrointestinal Hormones
REHFELD, J. F. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.4.1087 · Cited by 329
Blood Glucose Area Under the Curve: Methodological Aspects
Floch, J.-P. L., Escuyer, P., Baudin, E., Baudon, D., & Perlemuter, L. (1990) · Diabetes Care · doi:10.2337/diacare.13.2.172 · Cited by 296
Glucose-Sensing in Glucagon-Like Peptide-1-Secreting Cells
Reimann, F., & Gribble, F. M. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2757 · Cited by 292
Glucose-Dependent Insulin Release from Genetically Engineered K Cells
Cheung, A. T., Dayanandan, B., Lewis, J. T., Korbutt, G. S., Rajotte, R. V., Bryer-Ash, M., Boylan, M. O., Wolfe, M. M., & Kieffer, T. J. (2000) · Science · doi:10.1126/science.290.5498.1959 · Cited by 292
GIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Bruce, D. G., Chisholm, D. J., Storlien, L. H., & Kraegen, E. W. (1988) · Diabetes · doi:10.2337/diab.37.6.736 · Cited by 232
Gastric Inhibitory Polypeptide: the neglected incretin revisited
Meier, J. J., Nauck, M. A., Schmidt, W. E., & Gallwitz, B. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00039-3 · Cited by 226
A Human Cellular Model for Studying the Regulation of Glucagon-Like Peptide-1 Secretion
Reimer, R. A. (2001) · Endocrinology · doi:10.1210/en.142.10.4522 · Cited by 217
GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells
Egan, J. M., Bulotta, A., Hui, H., & Perfetti, R. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.357 · Cited by 209
Self-citationConsoli, A., Nurjhan, N., Reilly, J. J., Bier, D. M., & Gerich, J. E. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114940 · Cited by 204
Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.
Wang, Y., Perfetti, R., Greig, N. H., Holloway, H. W., DeOre, K. A., Montrose-Rafizadeh, C., Elahi, D., & Egan, J. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119482 · Cited by 172
Self-citationQualmann, C., Nauck, M. A., Holst, J. J., øSrskov, C., & Creutzfeldt, W. (1995) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529509101597 · Cited by 170
Doyle, M. E., & Egan, J. M. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.377 · Cited by 161
Self-citationFrank, J. W., Saslow, S. B., Camilleri, M., Thomforde, G. M., Dinneen, S. F., & Rizza, R. A. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90382-8 · Cited by 157
Lee, A., Patrick, P., Wishart, J., Horowitz, M., & Morley, J. E. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00219.x · Cited by 156
Role of oxidative stress in advanced glycation end product-induced mesangial cell activation
Lal, M., Brismar, H., Eklöf, A., & Aperia, A. C. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00367.x · Cited by 137
Glucagon-Like Peptide-1 Augments Insulin-Mediated Glucose Uptake in the Obese State
Egan, J. M., Meneilly, G. S., Habener, J. F., & Elahi, D. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8743 · Cited by 131
Self-citationMaher, F., DAVIES-HILL, T. M., Lysko, P. G., Henneberry, R. C., & Simpson, I. A. (1991) · Molecular and Cellular Neuroscience · doi:10.1016/1044-7431(91)90066-w · Cited by 122
Egan, J. M., Montrose‐Rafizadeh, C., Wang, Y., Bernier, M., & Roth, J. (1994) · Endocrinology · doi:10.1210/endo.135.5.7956929 · Cited by 121
Self-citationIs glucagon-like peptide 1 an incretin hormone?
Nauck, M. A. (1999) · Diabetologia · doi:10.1007/s001250051165 · Cited by 112
Grimelius, L., Capella, C., Buffa, R., Polak, J. M., Pearse, A. G. E., & Solcia, E. (1976) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02890341 · Cited by 96
Damholt, A. B., Kofod, H., & Buchan, A. M. J. (1999) · Cell and Tissue Research · doi:10.1007/s004419900093 · Cited by 89
Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes
Egan, J. M., Meneilly, G. S., & Elahi, D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2002 · Cited by 83
Self-citationHeijnen, H. F. G., Oorschot, V., Sixma, J. J., Slot, J. W., & James, D. E. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.2.323 · Cited by 77
GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro
Gallwitz, B., Ropeter, T., Morys‐Wortmann, C., Mentlein, R., Siegel, E. G., & Schmidt, W. E. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00095-6 · Cited by 68
Meier, J. J., Gallwitz, B., & Nauck, M. A. (2003) · BioDrugs · doi:10.2165/00063030-200317020-00002 · Cited by 67
Theodorakis, M. J., Carlson, O. D., Muller, D. C., & Egan, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1692 · Cited by 62
Self-citationNauck, M. A., Siemsglüss, J., Ørskov, C., & Holst, J. J. (1996) · PubMed · Cited by 61
Larsson, L., & Moody, A. (1980) · Journal of Histochemistry & Cytochemistry · doi:10.1177/28.9.6997368 · Cited by 57
Colocalization of GLP‐1 and GIP in Human and Porcine Intestine
Mortensen, K., Lundby‐Christensen, L., & Ørskov, C. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07017.x · Cited by 52
Kreymann, B., Yiangou, Y., Kanse, S. M., Williams, G., Ghatei, M. A., & Bloom, S. R. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)81008-1 · Cited by 51
O'Harte, F. P. M., Mooney, M. H., Lawlor, A., & Flatt, P. R. (2000) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00214-7 · Cited by 47
Bloom, S. R., & Polak, J. M. (1978) · Proceedings of The Nutrition Society · doi:10.1079/pns19780037 · Cited by 45
Incretin hormone expression in the gut of diabetic mice and rats
Berghöfer, P., Peterson, R. G., Schneider, K., Fehmann, H. C., & Göke, B. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90251-1 · Cited by 39
Sjölund, K., Ekelund, M., Håkanson, R., Moody, A. J., & Sundler, F. (1983) · Journal of Histochemistry & Cytochemistry · doi:10.1177/31.6.6188783 · Cited by 26
Role of Alterations in Systemic, Hepatic, and Muscle Lactate and Alanine Metabolism
Consoli, A., Nurjhan, N., Bier, D. M., & Gerich, J. E. (1990) · Cited by 26
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Short-chain fatty acids in control of body weight and insulin sensitivity
Canfora, E. E., Jocken, J. W., & Blaak, E. E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.128 · Cited by 2,298
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995
Self-citation
Metadata
- Authors
- Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2006-03
- Volume
- 290
- Issue
- 3
- Pages
- E550-E559
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2132613598
- Cited by
- 396
- References
- 57
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.